Table 3 Important human T cell receptors in cancer immunotherapy
Receptor family | Cluster of Designation | Ligands |
|---|---|---|
Activating receptors | Â | Â |
T cell receptor complex | CD3 | MHC:peptide |
Co-receptors | Â | Â |
CD2 | CD 2 | CD58 |
CD4 | CD4 | MHC class II |
CD5 | CD5 | CD72 (?) |
CD8 | CD8 | MHC class I |
CD27 | CD27 | CD70 |
Activating receptors | Â | Â |
CD28 | CD28 | B7.1 (CD80), B7.2 (CD86), B7H2 (CD275) |
OX40 | CD134 | OX40L (CD252) |
4-1-BB | CD137 | CD137L |
CD40L | CD154 | CD40 |
DNAM-1 | CD226 | PVR (CD155), PVR2 (CD112) |
TACI | CD267 | BAFF (CD257), APRIL (CD256) |
BCMA | CD269 | BAFF (CD257), APRIL (CD256) |
ICOS | CD278 | B7H2 (CD275) |
GITR | CD357 | GITRL (-) |
BAFFR | n/a | BAFF (CD257) |
Inhibitory receptors | Â | Â |
B7.1 | CD80 | PDL-1 (CD274), CD28, CTLA4 (CD152) |
CTLA4 | CD152 | B7.1(CD80), B7.2(CD86), B7H2 (CD275) |
CD160 | CD160 | HVEM (-) |
CD200R | CD200R | CD200 |
LAG-3 | CD223 | MHC class II, other? |
2B4 | CD244 | CD48 |
LIGHT | CD258 | HVEM (-) |
BTLA | CD272 | HVEM (-) |
PDL-1 | CD274 | PD-1 (CD279) |
PD-1 | CD279 | PD-L1 (CD274), PDL-2 (CD273) |
TIM-3 | n/a | Galectin-9 (-), other? |
TIGIT | n/a | PVR (CD155), PVR2 (CD112) |
VISTA (PD-1H) | n/a | B7H4 (-), other? |
B7H4 | n/a | Unknown |
KLRG-1 | n/a | E-Cadherin (CD324) |